Risk of hypertension in erenumab-treated patients with migraine: Analyses of clinical trial and postmarketing data

David W. Dodick, Stewart J. Tepper, Jessica Ailani, Nicola Pannacciulli, Marco S. Navetta, Brett Loop, Feng Zhang, Ani C. Khodavirdi, Allison Mann, Ahmad Abdrabboh, Jawed Kalim

Research output: Contribution to journalArticlepeer-review


Objective: To assess the risk of hypertension in patients with migraine who received erenumab in clinical trials and in the postmarketing setting. Background: Erenumab is a monoclonal antibody for migraine prevention that targets the calcitonin gene-related peptide (CGRP) receptor. Hypertension is a theoretical risk for inhibitors of the CGRP pathway. Although no evidence of an association between erenumab treatment and hypertension was observed during the clinical development program, adverse events (AEs) of hypertension have been identified in the postmarketing setting. Methods: Safety data from four phase 2 and phase 3 clinical trials were used to perform a pooled analysis of hypertension AEs in patients with migraine receiving erenumab. Postmarketing AEs of hypertension were identified from the Amgen Global Safety database from May 17, 2018, through January 31, 2020. Results: In the pooled analysis of clinical trials, hypertension AEs (placebo, 9/1043 [0.9%]; erenumab 70 mg, 7/893 [0.8%]; erenumab 140 mg, 1/507 [0.2%]) and percentage of patients initiating medication to treat hypertension (12/1043 [1.2%], 7/893 [0.8%], 1/507 [0.2%], respectively) were similar across treatment groups. A total of 362 AEs of hypertension were identified from the postmarketing setting, 26.2% (95/362) of which were serious, >245,000 patient-years of exposure. The exposure-adjusted incidence of hypertension was 0.144 per 100 patient-years. Conclusions: Clinical trials did not demonstrate an increased risk of hypertension with erenumab compared with placebo, and AE rates of hypertension reported with erenumab in the postmarketing setting were generally low. Additional data are needed to fully characterize the extent to which hypertension is a risk associated with erenumab.

Original languageEnglish (US)
Pages (from-to)1411-1420
Number of pages10
Issue number9
StatePublished - Oct 2021


  • blood pressure
  • calcitonin gene-related peptide
  • drug safety
  • hypertension
  • individual case safety report
  • postmarketing surveillance

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'Risk of hypertension in erenumab-treated patients with migraine: Analyses of clinical trial and postmarketing data'. Together they form a unique fingerprint.

Cite this